CagriSema Reports 22.7% in REDEFINE-1 — a Clear Step Past Semaglutide Alone (Dec 2025)

Novo Nordisk's answer to tirzepatide reported its pivotal result in late 2025: CagriSema — cagrilintide, an amylin analog, co-formulated with semaglutide — averaged 22.7% body-weight reduction at 68 weeks in REDEFINE-1.

The number landed in an awkward gap: clearly beyond semaglutide alone (14.9% in STEP 1), numerically ahead of tirzepatide's 20.9% SURMOUNT-1 average, yet below the ~25% the market had priced in, and without a head-to-head against the incumbent. The mechanism is the interesting part — amylin agonism adds a distinct satiety pathway to GLP-1 signaling, a different bet than tirzepatide's GIP route — and it broadened the field's conviction that combination incretin-adjacent therapy is where the ceiling moves next.

For the market we price, CagriSema is tomorrow's entrant with today's consequences: each credible next-generation readout pressures current self-pay pricing downward (the late-2025 Lilly and Novo price cuts landed in exactly this competitive climate) and shortens the runway for compounded programs whose entire case is a price gap. Pipeline context: orforglipron, retatrutide & CagriSema.